BioSpace News Archive

Endo International plc today announced that its subsidiaries Endo Pharmaceuticals Inc. and Par Pharmaceutical, Inc. have executed a Settlement Agreement with the State of Oklahoma.

Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) (“Portola " or the “Company”) for violations of federal securities laws.

Skanska has signed a contract with North Shore University Hospital to construct the new advanced surgical pavilion at their campus in Manhasset, New York, USA.

Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced certain preliminary unaudited fourth quarter and full year 2019 revenue results.

Eli Lilly and Company (NYSE: LLY) and Dermira, Inc. (NASDAQ: DERM) today announced a definitive agreement for Lilly to acquire Dermira for $18.75 per share, or approximately $1.1 billion, in an all-cash transaction

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that it has received CE mark approval for its AlloSeq cfDNA kit, making it broadly available to transplant patients and clinicians.

LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2 trial of LB-001,

Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a leading neurotech company focused on neurological wellness, today announced that it is the recipient of the Pioneer Technology Development Award for its development of the PoNS™ device.

Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento” or the “Company”), announced today that on January 9, 2020, it received a non-binding proposal from a private equity fund to acquire a majority or all of the issued and outstanding shares of the Company for up to $7.00 per share.

Generation Bio, a company leading a new generation of gene therapy, announced the closing of a $110 million Series C financing.